Introduction
Spasticity is a significant problem in many patients with cerebral palsy and if it is interfering with function, attempts to reduce its severity are desirable. Methods commonly employed include physical therapy, surgery, bracing, nerve-blocking techniques, electrical stimulation and drugs. Since dantrolene sodium became available, reports have appeared indicating that it has some efficacy in the treatment of spasticity in cerebral palsy (Chyatte and Basmajian 1973, Haslam et al. 1974 , Denhoff et al. 1975 , Ford et at. 
1976).
Although dantrolene sodium has been shown to be physiologically active in reducing the force of muscle response to peripheral nerve stimulation and in decreasing clonus (Basmajian and Super At the initial visit, a complete history and physical examination were performed by the physician. On the three subsequent visits the patient and family were questioned specifically about muscle spasms and range of motion that the family observed when dealing with the child, possible drug side-effects, activities of daily living, their general impression of the child's daily performance, and whether or not they thought the drug was helpful. These factors were rated by values from 1 to 9, with 5 being the pre-treatment baseline score, higher numbers indicating improvement (mild, moderate, marked) and lower numbers indicating deterioration.
Each of the four extremities was examined, and the following factors were given a numerical rating based on the following scoring system! tone (rated 0 to 6; 3=normal), clonus (0 to 6; 0 =normal), strength (0 to 5; 5 = normal), reflexes (0 to 6; 3=normal), spasms (0 to 3; 0 = normal). Spasms were rated by the severity of muscle contractions that were produced in other areas during the range-of-motion examination of a joint of one of the extremities. Mild spasms (rated 1) would include motion at another joint, such as knee flexion or extension occurring while the ankle was being examined. Severe spasms (rated 3) were, for example, a mass flexion pattern of the trunk and arms occurring while a leg was being examined. The scores for a given result from each extremity were totalled to produce the final score assigned to that particular examination.
Physiological measurements of the force of plantar flex.ion produced by,a tap on the tendo calcaneus, supramaximal tibia1 nerve stimulation, and voluntary plantar flexion were made in a slightly modified form of those described previously by Sheplan and Ishmael (1975) and Joynt (1976) . These tests were performed with the patient lying prone, and the foot held in a shoe strapped to a plate with the ankle at 90". The center of rotation of the foot-plate assembly was aligned with the patient's anatomical ankle-joint, and the number of foot-pounds of torque generated by plantar flexion against the foot-plate was measured by a strain gauge. The tendo calcaneus was tapped by a standard reflex hammer held by the examiner. Tibia1 nerve stimulation was performed by a bipolar surface stimulator placed over the mid-popliteal fossa and adjusted gradually to a supramaximal current.
Functional tests were applied to evaluate general activities of daily living. Tests for the arms and hands included unscrewing two halves of barrels of three sizes, buttoning and unbuttoning buttons of three sizes, following a pattern with a pencil on paper, and using each hahd separately to pick up and place a cylinder and to eat a marshmallow with a teaspoon. Tests of mobility were performed as they were applicable to a given individual, and included rolling, crawling, standing, walking (with aids if needed), wheelchair use, and climbing stairs. Only the appropriate tests of mobility were given: for example, wheelchair mobility was not tested in patients who did not use a wheelchair, nor was climbingstairs tested in a child who could not do so.-A total of 2 4 functional tests were performed.
Mobility tests for individual extremities were designed to measure motion in specific patterns. A board similar to that used by Stern et a/. (1969) was designed, with adjustable colored buttons (Fig. 1) . For testing the arms, the board was placed in front of the patient with the two closest buttons in the coronal plane, separated by JAMES A. LEONARD. Jr. in a horizontal .plane, then in a vk.tlal plane and then in a triangular pattern, so that shoulder adduction and abduction, shoulder and elbow flexion and extension: and a combination of these motions could be evaluated. For testing the legs, buttons were similarly placed to require adduction and abduction of the hip, and flexion and extension of the knee. A single button was used to test ankle plantar flexion and ._ .
dorsiflexion by a tapping motion on the button. Whenever a button was contacted with sufficient force, a click would be heard and a light would flash, indicating that a score had registered. The child was asked to touch the buttons in the prescribed pattern as quickly as possible, and the time taken to accomplish 10 button-contacts was recorded automatically by a timer. A total of 12 mobility tests of the extremities was performed. The functional and extremity mobility tests were quantified by the time (seconds) needed to perform the standard tasks. The m'aximum time allowed to complete a task was 60 seconds, so a score of 60 indicated either that the task actually took 60 seconds or that it could not be performed at all. Duplicate evaluations were performed for each task and the scores were averaged. Maximum cooperation was strongly encouraged by the examiners but was difficult to achieve at times, so there was considerable intertest variability for the same individual at different visits (see data tables).
Sixty-one variables were studied, including the 36 timed variables for testing function and mobility of extremities.
A double-blind procedure was used, with random assignment of patients to the two groups. The medication and placebo were pre-packaged in identical form and containers, and were identifiable by patient number only. A cross-over technique to compare drug and placebo in the same patient was not used because previous studies indicated that the presence of side-effects from dantrolene destroyed the blinding at the time of cross-over (Joynt 1976, Gelenberg and Poskanzer 1973) . The drug was provided in a Smg/cc suspension and was administered by a calibrated dropper or measuring cup, as appropriate. Following the initial evaluation (visit l), treatment was begun with a drug dosage of 4mg/kg/ day and was increased gradually during the next three weeks to an optimum level, 12mg/kg/day being the approximate maximum. The children were re-evaluated after three weeks (visit 2) and six weeks (visit 3). The drug was then discontinued and the children were tested again three weeks later (visit 4). At visit 2, dosage was adjusted to an optimum level depending on the results of the history and physical examination at that time, and was then maintained at this level until visit 3.
Other medications were not altered during the treatment period. Concomitant medications included mephobarbital, phenobarbital, phenytoin, antibiotics, decongestants, vitamins, imipramine and (in one patient) diazepam.
Data analysis
All data were converted to integers and placed in a computer for statistical analysis. For each variable, the change that occurred in each patient from visit 1 to each of the subsequent visits was determined, and drug-treated and placebo groups were compared. Thus the patient served as his own control, and only the differences from the initial testing values were analysed. The data tables show the initial (visit 1) test values, and subsequent columns indicate these differences.
As mentioned earlier, during the timed testing procedures a maximum of 60 seconds was allowed to perform a given test, Because the data were open-ended at the upper end, they would not follow a normal random distribution, so a nonparametric statistical procedure-the median test-was used to analyse the tests. (Ideally, in the placebo patients the inter-test difference would be zero.)
Results
Twenty-one patients with cerebral palsy and spasticity were originally examined. One patient on placebo discontinued treatment early because of lack of improvement, and would not return for further evaluation. One patient in the treated group (patient 1) discontinued the medicine after three weeks because of side-effects, but did return for a subsequent re-evaluation. This patient was therefore included in the analysis, although there were no visit 3 details. Thus 20 patients were included in the analysis, 11 of whom received the drug and nine the placebo. 
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'Positive numbers = increased torque: negative numbers = decreased torque.
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At ther beginning of the study the placebo and drug-treated groups were statistically similar, except that those in the drug-treated group were somewhat stronger ( Table 11) . (With the number of variables that were studied, it is to be expected that at least one might show a statistical difference at the 0.02 level.)
. There were 12 male and eight female children in the study. Ages ranged from four to 15 years. Diagnostic categories are shown in Table I . Etiology in the patient with paraparesis was undetermined: this child presented at nine years with progressive spastic paraparesis, not strictly cerebral palsy in the usual sense.
For the drug-treated patients, the average dantrolene dose was 7 -8mg/kg/ day (range 0.75 to 14-78mg) at visit 3, when theoretically the optimum dosage had been established. If the patient who discontinued the medicine because of early side-effects is excluded, the average dose was 8*35mg/kg/day (range 4.17 to 14 78mg).
Weight change at visit 3 was significant (p<O.O4), but not at visits 2 or4( Table 111) . The treated patients tended to lose weight slightly and the placebo patients to gain weight.
Several patients complained of sideeffects. There was a significant difference in the treated group at visit 2 (p<O*OO8), but not at visits 3 or 4 ( Table IV) . This suggests that side-effects tend to become less troublesome or to disappear with time. The reported side-effects included fatigue (five patients), drowsiness (three), anorexia (two), diarrhea (one) and vomiting (one). Analysis of historical reports from the patient and family indicated that spasms were reduced in the treated patients at visit 2 (p<0*09), but not subsequently (Table V) . Subjectively, reported improvement in range of motion was also better in the treated patients at visit 2 @<0.07) ( Table VI) . There was no statistical difference between the two groups in subjective reports from the patient or families regarding changes in activities of daily living, general daily performance, or whether or not the treatment appeared to be helpful.
The results of the physical examination (tone, clonus, strength, reflexes, spasms, blood pressure and pulse) showed no significant differences between the placebo and drug-treated groups, nor were changes in laboratory values significantly different.
Of the physiological tests performed, the response to tibia1 nerve stimulation showed a significant difference between the two groups. In the treated group a reduced response was seen at visit 2 @<0-03) and at visit 3 (p<O-O2), but not at visit 4 after the drug had been discontinued (Table VII) . The voluntary strength of plantar flexion was also reduced from placebo values at visit 3, but not at visit 2 (Table 11) .
The timed functional tests and extremity 'Positive numbers = improved; negative numbers = worsened. Improvement and deterioration were seen in a rather scattered and unrelated manner, and thus did not indicate conclusively that dantrolene produces significant functional improvement or decrement.
However, our studies did show that dantrolene was physiologically active in children, as it is in adults. The response to tibia1 nerve stimulation showed that the force of the muscle response was reduced significantly compared with placebo, and also that voluntary muscle strength was decreased, as occurs in adults (Joynt 1976) . In addition, no significant toxicity was found on clinical examination or by laboratory testing. When the drug was continued, side-effects were no greater after six weeks than with placebo. It would seem, therefore, that although dantrolene sodium is physiologically active, its usefulness in improving function in patients with spastic cerebral palsy is uncertain. It is possible that there may be some functional benefit in individual cases.
A double-blind study was carried out on 20 children with spasticity secondary to cerebral palsy, in order to compare the effects of dantrolene sodium suspension and a placebo. The drug was found to be physiologically active in reducing the force of muscle contraction, but objective functional improvement, as measured by multiple performance tests, was irregular and probably not significant. RBSUME Suspension de dantroikne sodium dans le traitement de Pinfirmite motrice dribrale Une etude en double aveugle a Ct C entreprise chez 20 enfants IMC spastiques, pour comparer une suspension de dantrolkne et un placebo. Le mkdicament s'est rCvClt physiologiquement actif en rkduisant la force de la contraction musculaire, mais I'amCloration fonctionnelle objective, mesurCe par de multiples Cpreuves de performance, a Ct C irrCgulikre et probablement non significative.
ZUSAMMENFASSUNG

Dantrolen Sodium Suspension zur Behandlung der spastischen Cerebralparese
Bei 20 Kindern mit einer Spastik aufgrund einer Cerebralparese wurde eine Doppelblindstudie durchgefiihrt, um die Wirkung von Dantrolen Suspension mit der eines Placebo zu vergleichen. Es stellte sich heraus, da13 das Medikament physiologisch wirksam war, indem es die Muskelverspannung reduzierte, eine. objektive funktionelle Besserung dagegen war irregular und wahrscheinlich nicht signifikant, was anhand von verschiedenen Tests festgestellt wurde.
RESUMEN
Suspensidn de dantrolene sddico en el tratamiento de la pardisis esphtica cerebral Se realizb un estudio doble-ciego en 20 nifios con espasticidad secundaria a parilisis cerebral, con el objeto de comparar 10s efectos de una suspensi6n de dantrolene y un placebo. Se ha116 que el firmaco era fisiolc5gicamente activo para reducir la fuerza de la contraccibn muscular, per0 la mejoria funcional objetiva medida por medio de diversos tests, de realizacibn, era irregular y probablemente no significativa.
